Document Detail

Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
MedLine Citation:
PMID:  11821468     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We tested the hypothesis that preoperative plasma levels of insulin-like growth factor (IGF) binding protein (BP)-2 or IGFBP-3 would predict cancer stage and prognosis in patients undergoing radical prostatectomy. MATERIAL AND METHODS: Plasma levels of IGF-I, IGFBP-2, and IGFBP-3 were measured preoperatively in 120 consecutive patients who underwent radical prostatectomy for clinically localized disease, postoperatively in 51 of these patients, in 44 healthy men, in 19 patients with metastases to regional lymph nodes, and in 10 patients with bone metastases. RESULTS: Plasma IGFBP-3 levels were lowest in patients with bone metastases (P < or = .043). IGFBP-2 levels were elevated in prostate cancer patients compared with healthy subjects (P < or = .006). However, within the group of prostatectomy patients, preoperative plasma IGFBP-2 levels were lower in patients with advanced disease (P < or = .033), were inversely correlated with prostatic tumor volume (P =.037), and declined after prostate removal (P =.044). Lower preoperative IGFBP-2 and IGFBP-3 levels and biopsy Gleason score were independent predictors of biochemical progression (P =.043, P =.040, and P =.020, respectively). In patients with disease progression, preoperative plasma IGFBP-3 levels were lower in those with aggressive than in those with nonaggressive failure (P =.042). CONCLUSION: Elevation of plasma IGFBP-2 levels in prostate cancer patients apparently is due to increased release directly from the prostate. For patients with clinically localized prostate cancer, preoperative plasma IGFBP-2 levels are inversely associated with biologically aggressive disease and disease progression. Preoperative plasma IGFBP-3 levels were decreased in patients with prostate cancer metastases and were an independent predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.
Shahrokh F Shariat; Dolores J Lamb; Michael W Kattan; Cuong Nguyen; JaHong Kim; Josie Beck; Thomas M Wheeler; Kevin M Slawin
Related Documents :
15686508 - Ca 125 levels in patients with non-hodgkin lymphoma and other hematologic malignancies.
6346628 - Chlamydia trachomatis in 'abacterial' prostatitis: microbiological, cytological and ser...
20090508 - Carbonic anhydrase i, ii, and vi, blood plasma, erythrocyte and saliva zinc and copper ...
7690308 - Haemodilution during transurethral resection of the prostate using water as the irrigan...
7330168 - Rheumatoid cervical myelopathy.
22273988 - Increased tlr2 expression on blood monocytes in irritable bowel syndrome patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  20     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2002 Feb 
Date Detail:
Created Date:  2002-03-07     Completed Date:  2002-03-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  833-41     Citation Subset:  IM    
Baylor Prostate Center and Male Reproductive Medicine and Surgery, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Progression
Insulin-Like Growth Factor Binding Protein 2 / blood*
Insulin-Like Growth Factor Binding Protein 3 / blood*
Insulin-Like Growth Factor I / analysis*
Lymphatic Metastasis
Neoplasm Invasiveness
Neoplasm Metastasis
Prostatic Neoplasms / blood,  pathology*,  surgery
Tumor Markers, Biological / blood
Reg. No./Substance:
0/Insulin-Like Growth Factor Binding Protein 2; 0/Insulin-Like Growth Factor Binding Protein 3; 0/Tumor Markers, Biological; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Up-to-date long-term survival curves of patients with cancer by period analysis.
Next Document:  Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhoo...